Human Investing LLC Takes $39,000 Position in Laboratory Co. of America Holdings (NYSE:LH)

Human Investing LLC acquired a new position in Laboratory Co. of America Holdings (NYSE:LH) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 169 shares of the medical research company’s stock, valued at approximately $39,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. AMF Tjanstepension AB boosted its position in shares of Laboratory Co. of America by 37.0% during the 3rd quarter. AMF Tjanstepension AB now owns 86,026 shares of the medical research company’s stock worth $19,232,000 after purchasing an additional 23,221 shares during the period. Exchange Traded Concepts LLC grew its stake in shares of Laboratory Co. of America by 1,962.5% in the third quarter. Exchange Traded Concepts LLC now owns 990 shares of the medical research company’s stock valued at $221,000 after buying an additional 942 shares in the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd raised its holdings in shares of Laboratory Co. of America by 22.3% in the 3rd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 9,538 shares of the medical research company’s stock valued at $2,132,000 after buying an additional 1,738 shares during the period. Raymond James & Associates lifted its stake in Laboratory Co. of America by 4.9% during the 3rd quarter. Raymond James & Associates now owns 124,336 shares of the medical research company’s stock worth $27,787,000 after acquiring an additional 5,786 shares in the last quarter. Finally, OLD National Bancorp IN boosted its stake in shares of Laboratory Co. of America by 24.7% in the third quarter. OLD National Bancorp IN now owns 1,878 shares of the medical research company’s stock valued at $420,000 after purchasing an additional 372 shares during the period. Institutional investors and hedge funds own 95.94% of the company’s stock.

Analyst Upgrades and Downgrades

LH has been the topic of several recent research reports. Morgan Stanley upped their target price on shares of Laboratory Co. of America from $260.00 to $270.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 17th. Barclays decreased their target price on Laboratory Co. of America from $271.00 to $260.00 and set an “equal weight” rating for the company in a report on Friday, February 7th. Evercore ISI raised Laboratory Co. of America from an “in-line” rating to an “outperform” rating and boosted their target price for the stock from $260.00 to $265.00 in a research note on Tuesday, January 7th. Robert W. Baird boosted their price objective on Laboratory Co. of America from $282.00 to $289.00 and gave the stock an “outperform” rating in a research report on Friday, October 25th. Finally, Bank of America lifted their price target on shares of Laboratory Co. of America from $262.00 to $271.00 and gave the stock a “buy” rating in a research note on Friday, December 13th. Three investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $265.31.

Insider Activity

In other news, EVP Der Vaart Sandra D. Van sold 1,000 shares of the company’s stock in a transaction that occurred on Thursday, November 21st. The stock was sold at an average price of $239.42, for a total transaction of $239,420.00. Following the completion of the sale, the executive vice president now owns 2,670 shares in the company, valued at $639,251.40. This represents a 27.25 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Adam H. Schechter sold 6,121 shares of Laboratory Co. of America stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $244.62, for a total transaction of $1,497,319.02. Following the completion of the transaction, the chief executive officer now owns 86,445 shares in the company, valued at approximately $21,146,175.90. This trade represents a 6.61 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 24,504 shares of company stock valued at $5,905,692. Insiders own 0.85% of the company’s stock.

Laboratory Co. of America Stock Performance

NYSE LH opened at $246.74 on Tuesday. The company has a market capitalization of $20.64 billion, a PE ratio of 27.98, a P/E/G ratio of 1.84 and a beta of 1.07. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.44 and a quick ratio of 1.30. Laboratory Co. of America Holdings has a 1 year low of $191.97 and a 1 year high of $258.59. The company has a fifty day moving average of $237.42 and a two-hundred day moving average of $231.14.

Laboratory Co. of America (NYSE:LH) last issued its quarterly earnings data on Thursday, February 6th. The medical research company reported $3.45 earnings per share for the quarter, beating analysts’ consensus estimates of $3.40 by $0.05. Laboratory Co. of America had a return on equity of 15.29% and a net margin of 5.73%. As a group, analysts expect that Laboratory Co. of America Holdings will post 15.96 earnings per share for the current year.

Laboratory Co. of America Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 12th. Shareholders of record on Thursday, February 27th will be paid a $0.72 dividend. The ex-dividend date of this dividend is Thursday, February 27th. This represents a $2.88 dividend on an annualized basis and a yield of 1.17%. Laboratory Co. of America’s dividend payout ratio is presently 32.65%.

About Laboratory Co. of America

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.